Tech Company Financing Transactions
Amylyx Pharmaceuticals Funding Round
On 8/24/2016, Amylyx Pharmaceuticals raised $5 million in Series A funding from Morningside Group and private investors.
Transaction Overview
Company Name
Announced On
8/24/2016
Transaction Type
Venture Equity
Amount
$5,000,000
Round
Series A
Investors
Morningside Group (Lead Investor) (Isaac Cheng)
private investors (Henri Termeer)
Proceeds Purpose
Our investment in Amylyx is aligned with the Fund's goals of driving medical advancement for this terrible disease.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
43 Thorndike St.
Cambridge, MA 02141
USA
Cambridge, MA 02141
USA
Phone
Undisclosed
Website
Email Address
Overview
Amylyx is an IND-enabling stage biopharmaceutical company dedicated to providing innovative, disease-modifying solutions for neurodegenerative diseases. We have a highly creative and motivated team focused on streamlined clinical development and drug discovery.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Joshua Cohen
Chief Executive Officer
Justin Klee
Chief Financial Officer
James Frates
Chief Medical Officer
Patrick Yeramian
Chief Scientific Officer
Kent Leslie
VP - Bus. Development
Margaret Olinger
VP - Human Resources
Debra Canner
Browse more venture capital transactions:
Prev: 8/24/2016: SmartEquip venture capital transaction
Next: 8/24/2016: ThreatQuotient venture capital transaction
Share this article
About Database of VC Transactions
We record every notable VC transaction. VC transactions reported here are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs